Pharmaceuticals News

– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2...

AC Immune receives Fast Track designation and IND clearance from the FDA for anti-alpha-synuclein active immunotherapy to treat early Parkinson's disease

Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from...

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data...

Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and...

Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular...

Once-weekly intravenous treatment was associated with reported improvements in finger function and walking ability, with no adverse events reported during treatment BOSTON, MA, Aug. 11, 2026 (GLOBE...

Dark Horse Consulting Group launches DHCG China, appointing Kang Liu, Ph.D. as Senior Director, Head of China, to guide developers through the IIT pathway.

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 millionExpanded CARVYKTI® availability to 348 global sites and 19...

Kailera Therapeutics, Inc., today announced the appointment of Nur Nicholson as Chief Technology Officer, effective August 31, 2026.